Weeks After $74 Billion Acquisition, Celgene Strikes Two Cancer Deals
Ahead of being absorbed by Bristol-Myers Squibb, Celgene forged a strategic collaboration with two companies to develop immuno-oncology treatments and cell therapies.
The Home of the Life Sciences Industry
Explore Latest News
What’s Next? Eli Lilly’s Lartruvo Flunks Sarcoma Trial
Eli Lilly’s ANNOUNCE Phase III clinical trial of Lartruvo (olaratumab) in advanced or metastatic soft tissue sarcoma failed to meet the primary endpoints of overall survival.
- Brain-Eating Amoeba Infections Are Rare, but Deadly—Research Is Working on a Cure
- Behind the Scenes at Lilly and Loxo's Whirlwind Wedding
- J&J and Apple Team up for AFib Program With Apple Watch
- January 18 Research Roundup: Skin Cancer, Turning Cancer Cells Into Fat Cells, and a Longevity Test
- Novartis and Oxford University Tie up a Big Data Agreement
Get personalized job alerts
Create a job alert and receive custom job recommendations straight to your inbox.
Employers
Post jobs on BioSpace and start building your talent pipeline today. Click the button to access our easy eCommerce site, which lets you purchase and post jobs in just a few clicks.